Featured Auburn Varicose Veins
Total Vein Treatment Center
134 North Street
Auburn NY 13021
1-866-381-4396
About Total Vein Treatment Center
Dr. David Locastro is a board certified general surgeon, a Fellow of the American College of Surgeons and a member of the American College of Phlebology. His practice is committed exclusively to the treatment of veins including tiny spider veins to large varicose veins. Dr. Locastro has a particular interest and experience in treating difficult cases with people who either have significant venous stasis ulcers or people who have been operated on before and have recurrent disease.
Dermatologists Mark Taylor, M.D. and Christine Whitelaw, M.D. demonstrate http://www.videoshelf.com/laser_hair_removal.html [laser hair removal] on the face, underarms, back, bikini area, and legs.
Read more
SAN MATEO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- BioForm Medical, Inc.
(Nasdaq: BFRM) announced today that it is scheduled to present at the 2008
Maxim Group Growth Conference on Tuesday, October 7, 2008. Derek Bertocci,
Chief Financial Officer of BioForm Medical, is scheduled to provide a
corporate overview of the Company at 2:30 p.m. (ET) in New York City.
Read more
SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc.
(Nasdaq: BFRM) today announced that the pivotal clinical study of Polidocanol,
conducted in Germany by BioForm Medical's partner, Chemische Fabrik KREUSSLER
& Co. GmbH (Kreussler), successfully met the study primary endpoint and has
been submitted to FDA as part of a New Drug Application (NDA) process.
Read more
SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc.
(Nasdaq: BFRM) today announced its financial results for the fourth quarter
and full fiscal year ended June 30, 2008. Net sales were $16.7 million for the
quarter ended June 30, 2008 as compared to $15.4 million for the quarter ended
June 30, 2007, an increase of $1.3 million or 8.4%. The net loss was
$20.0 million for the quarter ended June 30, 2008 as compared to a net loss of
$4.9 million for the quarter ended June 30, 2007. Net sales were $67.5 million
for fiscal year 2008 as compared to $47.4 million for fiscal year 2007, an
increase of $20.1 million or 42.4%. The net loss was $29.5 million for the
fiscal year 2008 as compared to $13.6 million for fiscal year 2007. The
$20.0 million net loss in the fourth quarter and the $29.5 million net loss
for fiscal year 2008 each included an $11.2 million charge for acquired
in-process research and development arising from the purchase of substantially
all assets of Advanced Cosmetic Intervention, Inc. (ACI) in April 2008.
Read more
